Organovo is one of the most fascinating companies that we follow–and quite continually–as the dynamic company has kept the momentum rolling with one scientific breakthrough after another.
Famous for the design and creation of functional human tissues for medical applications, we’ve recently also been following Organovo and other partnerships in researching human tissue as well as offering the first 3D bioprinted liver product.
It’s just been recently announced that Uniquest signed a worldwide licensing agreement with Organovo to patent kidney cells from induced pluripotent stem cells (iPSCs). Professor Melissa Little and her team at Uniquest have actually been able to grow kidney tissue which should prove to be helpful in not only drug screening but also disease modeling and cell therapy.
Research, in the paper ‘Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis’ published recently in Nature, discusses the method by which Little and her team have been able to grow cell types basically by generating kidney cells containing nephrons. In identifying a way to collect the proper materials, they were indeed able to generate true kidney organoids.
“When transcription profiles of kidney organoids were compared to human fetal tissues, they showed highest congruence with first trimester human kidney,” stated the researchers in their paper. “Furthermore, the proximal tubules endocytose dextran and differentially apoptose in response to cisplatin, a nephrotoxicant. Such kidney organoids represent powerful models of the human organ for future applications, including nephrotoxicity screening, disease modelling and as a source of cells for therapy.”
Together the teams will be working to develop the science, research, and development further of the kidney tissue.
“The mini-kidney we have been able to grow is very complex and more like the real organ,” Professor Little said. “This is important for drug testing as we hope these mini-kidneys will respond to the drugs as a normal organ might.”
While the mini-kidney is a huge step, it’s important to note that with the recent research, they have gone much further with developing kidney tissue. Organovo figures clearly into the picture as they will be using their famed bioprinting technology to separately develop a ‘kidney proximal tubule tissue’ that they project being released in 2016.
“We are excited to license this groundbreaking technology to enable the development of human kidney tissues that could change the landscape of drug testing and kidney research. Working with leading scientists such as Professor Little extends our leadership position in the generation and commercialization of tissues that better recreate in vivo human biology,” said Organovo’s Chief Technology Officer, Sharon Presnell, Ph.D.
Organovo will also continue to work with Professor Little in developing the intellectual property in extremely valuable and commercial applications for the kidney tissue, such as:
- Kidney disease modeling
- Nephrotoxicity screening
- Examining compounds to improve function in patients with renal disease
“This deal is anchored in world-leading induced pluripotent stem cell research by Professor Melissa Little and follows a research collaboration between The University of Queensland and Organovo, facilitated by UniQuest.,” said UniQuest CEO Dr. Dean Moss. “We are delighted to work with Organovo so that they can further develop and commercialise the technology to accelerate the drug discovery process and enable treatments to be developed faster and at lower cost.”
This partnership is certainly one we’ll be following as Organovo will be granted development and commercialization rights for applications regarding in vitro while Uniquest will be receiving ‘technology access fees’ and royalty payments.
The paper ‘Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis‘ was authored by Minoru Takasato, Pei X. Er, Han S. Chiu, Barbara Maier, Gregory J. Baillie, Charles Ferguson, Robert G. Parton, Ernst J. Wolvetang, Matthias S. Roost, Susana M. Chuva de Sousa Lopes, and Melissa H. Little.
Let’s hear your thoughts on this partnership and what it may mean within the bioprinting space. Discuss in the Organovo / Uniquest forum thread on 3DPB.com.
You May Also Like
Researchers See Potential for 3D Printed Inhalers
US researchers created a study to compare conventionally made inhaler actuators with those that were 3D printed. The results were promising, as outlined in the recently published ‘Supporting Inhalation Drug-Device...
What Does the Future Hold for Additive Manufacturing for Medical Devices in 2020?
Personalised medical devices are often cited to create the greatest opportunity in additive manufacturing (AM). There are a number of notable advantages that AM can bring to enhance the development...
Industrial Design and Development Company Chooses EnvisionTEC for the Production of Accurate Prototypes
P5 Designers (P5) is a traditional, project-based design and development business based in Milford, NJ. The company boasts dozens of patents in product, packaging and manufacturing design. P5 has built...
3D Printing in Africa: 3D Printing in Ghana
3D printing in Ghana can be considered to be in transition from the early to middle stage of development. This is in comparison with other active countries such as South...
View our broad assortment of in house and third party products.